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The cornea is avascular, enjoys relative immune privilege, and immunosuppressive treatment can be directly applied: yet data from all available reports indicate that allogeneic rejection is the commonest cause of corneal graft failure. In Australia, 5 year actuarial corneal graft survival is 72%: irreversible rejection accounts for at least 33% of all graft failures.' Graft survival is much shorter in certain high risk groups, with rejection being the primary cause of failure in a higher proportion."4 Moreover, graft survival figures give no indication of the number of patients denied the opportunity of a graft in the first place because of perceived high risk of rejection, and in corneal surgery at the present time the main strategy to reduce the impact of graft rejection is to avoid grafts in high risk cases.
The fact that rejection can be diagnosed, and its clinical course studied, by direct observation of corneal grafts obviates the need for histopathological study of biopsy specimens of graft. Biopsy of rejecting cornea could not be justified ethically. This constraint does not apply to human solid organ transplants: investigation of immunohistochemical, ultrastructural, and molecular aspects of rejection of kidney and other organs is well established and can guide clinical management. The virtual inaccessibility of rejecting human cornea from the biopsy standpoint, and the fact that grafts are seldom removed at the time of rejection, has two consequences for the investigation of mechanisms of graft rejection. Firstly, the corneal grafts on which pathological studies have been reported represent late or burnt out rejection. Secondly, most information on the sequence of events in rejecting corneas has been obtained from experimental animal models. Thus, while corneal graft rejection presents clinical appearances familiar to ophthalmologists, our knowledge of pathology and mechanisms is comparatively fragmentary.
Incidence, clinical, and pathological features of corneal graft rejection Corneal graft rejection usually arises as an apparently isolated event, not associated with any other clinical abnormality. It is frequently the case, however, that rejection follows intercurrent inflammation such as that induced by suture loosening, suture track infection, or recurrent herpetic infection. Reported incidence of rejection in any series will depend on the indications for graft and other factors, but in the largest reported cohort of graft recipients, 18% have undergone at least one rejection episode.' Graft rejection of all types has been shown to have higher incidence in patients younger than 50 years than in those over 50.$ Endothelial rejection was shown, in the same series of graft recipients, to occur at an average interval of 8 months after graft, with a range of 2 weeks to 29 months. While rejection is unusual later than this time, unequivocal endothelial graft rejection has been observed by the author to occur as late as 9 years after graft. It is a manifestation of the relative immune privilege of the cornea that, in contrast, most solid organ transplants that succumb to rejection are lost within the first 3 months after graft.
The signs of corneal graft rejection most often seen in clinical practice indicate endothelial rejection. Earliest signs are limbal injection, aqueous cells, and small graft keratic precipitates. An endothelial rejection line is seen in longer established rejection, advancing across the graft and associated with corneal oedema (Fig 1) . Epithelial rejection lines and the nummular subepithelial infiltrates indicative of stromal graft rejection (Fig 2) are seen less frequently. These may be associated with only minor symptoms and are not usually accompanied by aqueous inflammation, unless followed after a short interval by endothelial rejection. In some graft recipients, the rejection of individual cell layers of the cornea thus described may overlap.5 In irreversible rejection the entire graft may become oedematous and opaque. On rare occasions, the rejection may be so potent that sloughing ofthe corneal stroma may occur.
Graft oedema indicates endothelial pump dysfunction, with an increase in thickness during a rejection episode occurring consequent to immunologically induced endothelial cell injury. Graft Experimental corneal aliograft rejection Review of animal corneal transplantation will here be restricted to experimental models oforthotopic full thickness allografts (homologous to clinical grafts) on which studies of rejection have been reported. The rabbit is the most widely used animal model because of the similar corneal size and appearance of graft rejection to that of humans, and the ease of post-graft examination with a slit-lamp microscope. In rabbits, unlike other animals, it is however necessary to overcome the corneal immune privilege of the normal eye in order to induce rejection. This is effected by donor strain skin grafting following corneal graft, transplantation into prevascularised cornea, or into an eccentric bed near the limbus. Rabbits were used in the early studies of rejection and Maumenee's report in 1951 presented the first evidence that late failure of corneal grafts could be caused by sensitisation of the host to donor antigens.'2 Several descriptions of rabbit corneal graft rejection have subsequently been reported.'"'5 Other animal models which have been described are the cat,'6 inbred rat,'7-'9 inbred mouse2"22 and sheep (Williams KA et al, submitted for publication).
Corneal graft rejection in animals resembles to varying degrees the appearance observed in humans. In 8, or in the overall study population.34 While intravenous methylprednisolone is the standard first line treatment of solid organ graft rejection, it is difficult to justify the use of potentially toxic systemic steroids in corneal rejection when a high proportion can be successfully treated with topical preparations.
There is an evident need for safe alternative immunosuppressive agents to treat graft recipients with steroid resistant rejection. Many of the published research studies on cyclosporin have investigated prevention rather than treatment of rejection, and investigated corneal penetration with different vehicles for topical administration in experimental models. Chen and colleagues examined rabbit corneal allograft survival following treatment with cyclosporin begun at the earliest sign of rejection and continued for 60 days: grafts treated with cyclosporin in collagen shields survived longer than those treated with drops in an olive oil vehicle. 35 Topical cyclosporin A 0-025% in an alpha cyclodextrin vehicle has been reported to suppress rabbit allograft rejection if commenced early in the episode.36 Topical FK506 administered in the same vehicle has also been shown to reverse established rejection in the rabbit model (Mills RA, personal communication).
Antibody therapy, which is frequently used in the treatment of solid organ graft rejection, has not yet been adopted in clinical corneal transplantation. This is despite the appealing prospect of local administration. Direct application of antibody to the eye might be effective in reversing rejection if expansion and maturation of alloantigen specific T lymphocytes occurs in situ rather than in the central lymphatic system (lymph nodes, blood, spleen); it also might diminish the problem of host response to systemically administered non-human proteins. Earliest reports described attempts to prevent, rather than treat, rejection episodes. Rabbit corneal allograft survival was prolonged by systemically administered heterologous antilymphocyte serum,3738 but not by an antirabbit pan-T cell monoclonal antibody F(ab')2 fragment ricin A chain conjugate.39 No effect on survival was observed with subconjunctival0 or topical4' antilymphocyte serum or subconjunctival anti-T cell monoclonal antibody. 39 There have been interesting reports of local administration of monoclonal antibody to reverse corneal graft rejection. Ippoliti It is unclear whether the mechanisms of action of locally administered antibody are as simple as might be supposed, and these need to be thoroughly unravelled in order to direct the path of future clinical studies. We need a detailed understanding of the mechanisms underlying graft tolerance in experimental models of corneal allotransplantation. In general terms, it will be difficult to apply the information on immunosuppression obtained from animal models into clinical management. This is because corticosteroids, the principal immunosuppressive agents, are effective in reversal of a high proportion of corneal allograft rejection episodes and cannot be excluded from a treatment protocol without compelling reasons.
There is wide agreement that corneal allograft rejection is T cell mediated, but information on 
